Pulse Biosciences Inc. released its first quarter 2025 financial results, reporting a GAAP net loss of $16.8 million, which marks an increase from the $10.1 million net loss recorded in the same period last year. The company's non-GAAP net loss for the quarter was $11.4 million, compared to $8.1 million in the prior year period. Cash and cash equivalents as of March 31, 2025, totaled $119.3 million, a substantial increase from $34.9 million as of March 31, 2024, and a slight increase from $118.0 million as of December 31, 2024. The increase in cash balance includes $14.1 million in net proceeds from the exercise of warrants in the first quarter from a rights offering that closed in July 2024. Cash used in operating activities for the first quarter amounted to $13.5 million, up from $9.8 million in the same period the previous year. In terms of operational updates, Pulse Biosciences expanded its direct commercial resources in preparation for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The company also plans to initiate a U.S. clinical trial in mid-2025 to gather further evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules.